Browsing tag:

Europe


An article published in January 2015 in Diabetes, Obesity and Metabolism explored the pharmacodynamics and the benefits of Dapagliflozin and Canagliflozin in the fight against obesity and type 2 diabetes. This double-blind, randomized study involved both males and females between the ages of 18 and 55. All participants were deemed healthy and free of significant[…]

Read More

As the leading cause of blindness in the United States Diabetic Macular Edema {DME} is a serious concern for the growing aging population, affecting roughly one million Americans. The recent announcement from pSivida Corp. regarding the marketing authorization in the EU of their DME treatment Fluocinolone is hopeful for U.S. supporters of this formidable drug.[…]

Read More

Riociguat, CAS# 625115-55-1, was approved yesterday by the FDA for the treatment of thromboembolic pulmonary hypertension. Known as the brand name Adempas, Riociguat has proven in trials to be an efficacious treatment option for adults with both persistent and recurrent thromboembolic pulmonary hypertension. The patient population suffering from chronic (CTPH) or recurrent thromboembolic pulmonary hypertension is[…]

Read More

Levodopa is typically prescribed alongside carbidopa to treat Parkinson’s disease. Brand names Sinemet and Sinemet CR are comprised of levodopa and carbidopa, and systemic levodopa can be found under the names Dopar and Larodopa. Classified as a dopaminergic antiparkinsonism agent, levodopa is also used to treat Periodic Limb Movement Disorder and Restless Legs Syndrome when[…]

Read More

Carfilzomib, CAS number 868540-17-4, is a late-stage, selective next-generation proteasome inhibitor for patients with multiple myeloma. Developed by Onyx, carfilzomib has the ability to irreversibly bind to and inhibit the chymotrypsin-like activity of the 20S proteasome, which is an enzyme that degrades unwanted cellular proteins. The subsequent inhibition of the proteasome-mediated proteolysis creates  a build-up[…]

Read More

Stroke is the leading cause of neurologic disability in the US and Europe among adults. Worldwide, it is the second leading cause of death, trailing after coronary artery disease (CAD) in developed nations. In an ischemic stroke, the patient’s blood supply to certain parts of the brain is decreased, resulting to loss of function in[…]

Read More